Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Up 76.1% in July

Liminatus Pharma Inc. (NASDAQ:LIMN) saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 4,234,144 shares, a growth of 76.1% from the July 15th total of 2,404,454 shares. Currently, 10.4% of the company’s shares are short sold. Based on an average daily volume of 52,873,116 shares, the short-interest ratio is presently 0.1 days.

Liminatus Pharma Stock Up 4.3%

Shares of LIMN stock traded up $0.01 during trading hours on Monday, reaching $0.15. 1,162,643 shares of the stock traded hands, compared to its average volume of 20,955,160. Liminatus Pharma has a 1-year low of $0.10 and a 1-year high of $4.12. The business has a fifty day moving average price of $0.12 and a 200 day moving average price of $0.25. The firm has a market capitalization of $7.39 million, a PE ratio of -0.31 and a beta of 5.34.

Liminatus Pharma (NASDAQ:LIMN) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.03) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Liminatus Pharma in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.